ArticleJournal of intensive care2026
Early osmotherapy exposure and subsequent incident acute kidney injury in neurocritical care patients: a MIMIC-IV retrospective cohort study.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOsmotherapy is frequently used in neurocritical care to manage cerebral edema and intracranial hypertension. However, its association with subsequent new-onset acute kidney injury (AKI), and whether early serum sodium or chloride burden materially attenuates this association, remain uncertain.
methodsWe conducted a retrospective cohort study using MIMIC-IV version 3.1. Adult first-ICU neurocritical care patients were analyzed with a 48-h landmark design. The primary risk set included patients who were alive, remained in the ICU, and were AKI-free at 48 h after ICU admission. The primary exposure was any osmotherapy, defined as mannitol or hypertonic saline administered within the first 48 ICU hours, compared with no osmotherapy. The primary outcome was incident AKI after the 48-h landmark through ICU day 7 or ICU discharge. Multivariable regression was used as the main adjusted model; propensity-score weighting, overlap weighting, doubly robust models, and modified Poisson regression were used as complementary estimators. Sodium/chloride burden analyses were conducted in the lab-complete subset.
resultsThe final 48-h landmark cohort included 2,756 adult neurocritical care patients, of whom 624 (22.6%) developed incident AKI after the landmark. Any osmotherapy was administered to 365 patients (13.2%). In the doubly robust overlap-weighted logistic model, any osmotherapy was associated with subsequent incident AKI (OR, 1.48; 95% CI 1.12-1.96; P = 0.006). The corresponding doubly robust overlap-weighted modified Poisson estimate was RR 1.30 (95% CI 1.08-1.57; P = 0.006). Sodium/chloride burden analyses included 2,455 lab-complete patients. Early sodium burden (OR, 0.99; 95% CI 0.92-1.07; P = 0.792) and chloride burden (OR, 1.01; 95% CI 0.94-1.09; P = 0.743) did not materially attenuate the observed association in exploratory adjustment models. In exploratory clinical relevance analyses, patients with subsequent AKI had higher hospital mortality and lower creatinine-based renal recovery at ICU and hospital discharge. Dose-proxy and hypertonic saline concentration-specific analyses were exploratory because dose capture was incomplete and 23.4% hypertonic saline exposure was sparse.
conclusionsAmong adult neurocritical care patients who were alive, remained in the ICU, and were AKI-free at the 48-h landmark, early osmotherapy exposure was associated with a higher risk of subsequent incident AKI. This association was not materially attenuated by early serum sodium or chloride burden in exploratory adjustment models. These findings support careful renal monitoring in patients receiving clinically indicated osmotherapy, while residual confounding by indication precludes causal interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.